A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102

Docetaxel and vinorelbine have demonstrated Single-agent activity in breast cancer. Preclinical studies suggest potential synergy between these antitubulin chemotherapy agents. This study evaluates these drugs in combination in metastatic breast cancer. Taxane-naive patients with HER-2 negative, sta...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gralow, Julie R., Barlow, William E., Lew, Danika, Dammann, Kim, Somlo, George, Rinn, Kristine J., Vogel, Stanley J., Wong, Lucas, Livingston, Robert B., Hortobagyi, Gabriel N.
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2013
Teme:
Clinical Trial
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3889983/
https://ncbi.nlm.nih.gov/pubmed/24352574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-013-2797-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki